TY - JOUR
T1 - Impact of body mass index on adverse events after implantation of left ventricular assist devices
T2 - An IMACS registry analysis
AU - Forest, Stephen J.
AU - Xie, Rongbing
AU - Kirklin, James K.
AU - Cowger, Jennifer
AU - Xia, Yu
AU - Dipchand, Anne I.
AU - Sivathasan, Cumara
AU - Merry, Chris
AU - Lund, Lars H.
AU - Kormos, Robert
AU - Hannan, Margaret M.
AU - Nakatani, Takeshi
AU - Jorde, Ulrich
AU - Goldstein, Daniel J.
N1 - Funding Information:
Data collection for this work was funded in whole or in part with federal funds from the National Heart, Lung and Blood Institute, National Institutes of Health, Department of Health and Human Services (Contract Grant HHSN268201100025C).
Funding Information:
J.K.K. is the principal investigator (PI) of the INTERMACS registry and receives institutional support through INTERMACS funds. J.C. reports institutional grant support from Medtronic/HeartWare and Abbott/Thoratec. She is on the Medtronic steering committee, and has received research-related travel funds from Abbott. L.H.L. reports consulting for Novartis, Merck, Boehringer Ingelheim, Sanofi, Vifoir Pharma, and AstraZeneca. D.J.G. is a national PI for the MOMENTUM 3 clinical trial and consultant for Ethicon. He has received research-related travel funds from Abbott.
Publisher Copyright:
© 2018 International Society for Heart and Lung Transplantation
PY - 2018/10
Y1 - 2018/10
N2 - BACKGROUND: Limited data exist describing impact of body mass index (BMI) on post‒left ventricular assist device (post-LVAD) outcomes. We sought to define the relationship between body mass index (BMI) and adverse events (AEs) after LVAD implantation by examining the ISHLT Mechanically Assisted Circulatory Support (IMACS) registry. METHODS: Patients implanted with a contemporary continuous flow (CF)-LVAD were stratified into 4 groups using pre-operative BMI: underweight (UW; BMI ≤18.5 kg/m2); non-obese (NO; BMI >18.5 to <30 kg/m2); obese (OB; BMI ≥30 to <40 kg/m2); and morbidly obese (MO; BMI ≥40 kg/m2). Freedom from AEs was evaluated using the Kaplan–Meier method and risk factors for development of first AE were identified using multiphase parametric hazard modeling. AEs included infection, thromboembolic events, bleeding, device malfunction, and neurologic dysfunction. RESULTS: Between 2013 and 2015, a total of 9,408 patients underwent implantation of a CF-LVAD, which consisted of 368 (4%) UW, 5,719 (61%) NO, 2,770 (29%) OB, and 444 (5%) MO patients. Survival among the 4 BMI cohorts was similar at 2 years (70.8% to 75.8%, p = 0.24). MO patients were less likely to be free from a non‒VAD-related infection (p < 0.0001) or device-related infection (p = 0.0014) at 2 years (50.3%, 70.7%) when compared with OB (58.3%, 78.7%), NO (65.2%, 81.4%), and UW (68.9%, 77.4%) patients. UW (81.5%) and NO (81.3%) patients were more likely to be free from device malfunction at 2 years when compared with OB (78.3%) and MO (72.6%) (p = 0.0006). Thromboembolic events were rare and more common in the UW cohort (p = 0.026). CONCLUSIONS: Although BMI was not correlated with 2-year mortality, an increased rate of infectious and device-related AEs was noted in OB and MO LVAD patients. In a group with few options for transplant, the event morbidity in obese patients can be expected to impact morbidity with longer support durations.
AB - BACKGROUND: Limited data exist describing impact of body mass index (BMI) on post‒left ventricular assist device (post-LVAD) outcomes. We sought to define the relationship between body mass index (BMI) and adverse events (AEs) after LVAD implantation by examining the ISHLT Mechanically Assisted Circulatory Support (IMACS) registry. METHODS: Patients implanted with a contemporary continuous flow (CF)-LVAD were stratified into 4 groups using pre-operative BMI: underweight (UW; BMI ≤18.5 kg/m2); non-obese (NO; BMI >18.5 to <30 kg/m2); obese (OB; BMI ≥30 to <40 kg/m2); and morbidly obese (MO; BMI ≥40 kg/m2). Freedom from AEs was evaluated using the Kaplan–Meier method and risk factors for development of first AE were identified using multiphase parametric hazard modeling. AEs included infection, thromboembolic events, bleeding, device malfunction, and neurologic dysfunction. RESULTS: Between 2013 and 2015, a total of 9,408 patients underwent implantation of a CF-LVAD, which consisted of 368 (4%) UW, 5,719 (61%) NO, 2,770 (29%) OB, and 444 (5%) MO patients. Survival among the 4 BMI cohorts was similar at 2 years (70.8% to 75.8%, p = 0.24). MO patients were less likely to be free from a non‒VAD-related infection (p < 0.0001) or device-related infection (p = 0.0014) at 2 years (50.3%, 70.7%) when compared with OB (58.3%, 78.7%), NO (65.2%, 81.4%), and UW (68.9%, 77.4%) patients. UW (81.5%) and NO (81.3%) patients were more likely to be free from device malfunction at 2 years when compared with OB (78.3%) and MO (72.6%) (p = 0.0006). Thromboembolic events were rare and more common in the UW cohort (p = 0.026). CONCLUSIONS: Although BMI was not correlated with 2-year mortality, an increased rate of infectious and device-related AEs was noted in OB and MO LVAD patients. In a group with few options for transplant, the event morbidity in obese patients can be expected to impact morbidity with longer support durations.
UR - http://www.scopus.com/inward/record.url?scp=85053030246&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053030246&partnerID=8YFLogxK
U2 - 10.1016/j.healun.2018.06.004
DO - 10.1016/j.healun.2018.06.004
M3 - Article
C2 - 30195832
AN - SCOPUS:85053030246
SN - 1053-2498
VL - 37
SP - 1207
EP - 1217
JO - Journal of Heart and Lung Transplantation
JF - Journal of Heart and Lung Transplantation
IS - 10
ER -